Ruben Colman, MD, PhD

Want to connect? We will be at #ECCO26 later this week 👋

Grateful for former and current mentors incl. @IBDMD @GeertDHaens @PhilMinar @DrMichaelRosen.bsky.social and many others!

Precision Therapeutics for IBD Lab The mission of the Precision Therapeutics for IBD Lab (the Colman Lab) is to develop comprehensive tools that break the therapeutic ceiling through disease modification resulting in healing.

Study coordinator and post-doc positions coming soon! - Want to learn more? Follow us at colmanlab.stanford.edu

🔦We seek to break the therapeutic ceiling for IBD by fusing precision medicine approaches including:

📈Clinical pharmacology
🧪Molecular biomarker discovery
🔊Emerging (transmural) endpoints through @BowelUltrasound

📣Earlier this month we formally launched the @Stanford Precision Therapeutics for IBD Lab (the Colman Lab)!🧪 - @SMCH_IBD_Celiac @StanfordPedsGI @StanfordChild (1/5)

Come practice at the leading edge with an innovative and caring team! Stanford Pediatric GI is hiring clinician educator faculty at all ranks for positions based in the North and East Bay.
facultypositions.stanford.edu/en-us/job/49...
facultypositions.stanford.edu/en-us/job/49...

The global burden of inflammatory bowel disease: from 2025 to 2045 Nature Reviews Gastroenterology & Hepatology, Published online: 18 July 2025; doi:10.1038/s41575-025-01097-1The global burden of inflammatory bowel disease (IBD) is shifting as countries transition through four epidemiologic stages. This Perspective explores the global evolution of IBD over the next 20 years and proposes strategies for prevention and health-care innovation.

ICYMI: New online! The global burden of inflammatory bowel disease: from 2025 to 2045

Read our #SMCH_IBD_Celiac experience using Intensified Upadacitinib dosing for Adolescent Patients with Acute Severe Ulcerative Colitis. Now in #mdpichildren mdpi.com/3235924 @mdpiopenaccess.bsky.social #PerseusPatel @mosespedsibd.bsky.social @drmichaelrosen.bsky.social #StanfordPedsGI

Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky

Anthropometric Trajectories in Children Prior to Development of IBD This cohort study assesses the trajectory of anthropometric nutritional status in children before a diagnosis of inflammatory bowel disease (IBD) as well as growth recovery after diagnosis.

Anthropometric Trajectories in Children Prior to Development of IBD show impaired nutritional status as assessed by weight up to 3 years and by length or height 1 year before a diagnosis of CD and by weight up to 1 year before a diagnosis of UC

jamanetwork.com/journals/jam...